The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
An 11 April House Oversight Committee hearing with US Food and Drug Commissioner Robert Califf may be a sign that an era of relatively calm, bipartisan support for the agency on Capitol Hill is ending.
At a time when congressional Republicans and Democrats are at odds on so many aspects of government policy and public...
Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.
The new CDER director focused on plans to improve morale during an Aug. 8 townhall, but staff comments indicate that may be a challenge.
New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.
